On November 14th, AstraZeneca announced that Infineon&Co; Reg; (English trade name: IMFINZI®, common name: Duvalizumab) has officially obtained approval from the National Drug Administration on November 7th for the combination of gemcitabine and cisplatin for first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) in adult patients. This plan is the first approved immunotherapy plan for biliary tract cancer in China.